Distinct Type of Myeloid Neoplasms Characterized by Germline DDX41 Mutations
Researchers conducted a retrospective study to comprehensively characterize DDX41 mutations in a multinational cohort of patients with MNs.
Researchers conducted a retrospective study to comprehensively characterize DDX41 mutations in a multinational cohort of patients with MNs.
Researchers sought to determine if momelotinib provided better improvements in anemia in patients with myelofibrosis, compared with treatment with danazol.
Researchers sought to verify the association of mutations in the splicing pathway gene SF3B1 with low bone marrow blast counts and increased ring sideroblasts in MDS.
Preclinical research suggests that a monoclonal antibody may be effective for treating CALR-mutant myeloproliferative neoplasms.
The symptoms and care needs of patients with myeloproliferative neoplasms are discussed in a report on effective care management for these patients.
Researchers sought to determine the role of lenalidomide in the pathogenesis of therapy-related myeloid neoplasms.
Researchers sought to determine the efficacy of endoscopic management of recurrent GVB in patients with MPN.
Researchers sought to determine risk factors for developing secondary myeloid neoplasm in patients with severe aplastic anemia.
Researchers sought to determine whether there was a higher risk of developing thrombosis in patients with MPNs and COVID-19.
The approval was based on data from the phase 2 FIGHT-203 study, which included 28 patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.